Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) has provided an update.
Zymeworks will showcase new clinical and preclinical data from its antibody-drug conjugate portfolio, including the folate receptor alpha-targeting ZW191 and a novel pan-RAS inhibitor ADC platform, at the AACR Annual Meeting in San Diego. The company plans an oral presentation on updated Phase 1 data for ZW191, which has shown encouraging single-agent activity and a differentiated safety profile in heavily pretreated patients with advanced solid tumors.
Complementary poster presentations will highlight preclinical findings that ZW191 combines effectively with standard-of-care agents such as carboplatin, paclitaxel, bevacizumab, and PARP inhibitors, suggesting potential to improve efficacy across multiple cancer types. Zymeworks will also present data on new ADC candidates, including ZW437 and ZW418, built on a pan-RAS inhibitor platform designed to deliver higher potency with improved tolerability in RAS-mutant cancers, underscoring its bid to strengthen its position in next-generation oncology therapeutics.
The most recent analyst rating on (ZYME) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Overall score reflects a strong earnings-call outlook (clinical validation, regulatory path, improved FY2025 performance, and nondilutive financing) offset by weak underlying financial performance (recent losses and ongoing cash burn) and neutral technicals; valuation remains challenged due to unprofitability (negative P/E).
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a biotechnology company that manages a portfolio of licensed healthcare assets while advancing a pipeline of novel, multifunctional biotherapeutics. The company focuses on antibody-drug conjugates and targeted cancer therapies, aiming to address difficult-to-treat solid tumors across indications such as ovarian, endometrial, non-small cell lung, pancreatic, and colorectal cancers.
Average Trading Volume: 766,246
Technical Sentiment Signal: Buy
Current Market Cap: $1.75B
See more insights into ZYME stock on TipRanks’ Stock Analysis page.